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The effect of hydralazine treatment on 3 murine tumours (RIF-I, KHT and 16/C) was monitored using 31P-NMR. 
Changes in the 31p-NMR spectrum are compared with measurements of radiobiological hypoxic fraction (RHF) in the 
RIF-1 and KHT. Hydralazine is known to reduce temporarily blood flow in experimental tumours, and thus cause a 
transient increase in the RHF to 100% (in RIF-1 and KHT). This correlates with a decline in energy status as measured 
by 31p-NMR (i.e. there was an increase in Pi in all three tumours). Time-course data from the RIF-I and KHT tumours 
show that maintenance of anaesthesia prolongs the hypoxia induced by hydralazine. 
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1. INTRODUCTION 
Most solid tumours are believed to contain some 
hypoxic cells, which can make them resistant o 
radiotherapy [1]. The relationship between oxygen 
tension and proportion of tumour cells that are 
hypoxic, the radiobiological hypoxic fraction 
(RHF), has been studied in detail but how this 
depends on cellular energetics i not known. 
Tumours have been investigated by phosphorus 
NMR in experimental [2,3] and clinical [4] situa- 
tions. Metabolic response to therapy [2,5] has been 
studied and a correlation between blood flow and 
tumour energy status has been reported [6]. 
Hydralazine, an anti-hypertensive agent, alters 
tissue perfusion and increases the resistance of ex- 
perimental tumours to radiation [7]. This 
resistance has been attributed to the 'steal' 
phenomenon, whereby tumour perfusion is 
decreased when blood flow to other tissues is in- 
creased. Induction of severe hypoxia in tumours 
can greatly increase the effect of bioreductive 
agents [7,8]. 
NMR data showing changes in tumour 
energetics following hydralazine treatment have 
been reported [9,10], but no attempt has been 
made to correlate these data with RHF. We now 
report the results of studies on the effects of 
hydralazine on three experimental tumours as 
monitored by 31p-NMR, and in 2 tumours as 
monitored by changes in the RHF. Two questions 
addressed were the effectiveness of hydralazine on 
changing the energy status of these tumours, and 
whether there is a time-course r lationship between 
the RHF and energy status of tumours. 
2. MATERIALS AND METHODS 
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2.1. Mice and tumours 
The KHT sarcoma [11], RIF-1 fibrosarcoma [12] and 16/C 
mammary carcinoma [13] were implanted subcutaneously in 
category 1V CBH/He mice in the mid-dorsal pelvic region of 
the back. Mice were treated with radiation or subjected to NMR 
analysis when tumours attained a mean diameter of 6-8 mm. 
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2.2. Tumour irradiation and assay response 
Tumours in mice were locally irradiated with 250 kV X-rays 
as in [14]. Each tumour was assayed individually [15]. Tumours 
were excised 24 h after treatment, single-cell suspensions 
prepared, and appropriate cell members plated as described for 
KHT [15] and RIF-1 [12] tumours. Following incubation for 14 
days, colonies of 50 or more cells were scored as survivors. 
2.3. Animal anaesthesia 
Mice were treated intraperitoneally with a 1 : 1 : 2 mixture of 
hypnorm : hypnovel : H20 initially at a dose of  0.2 ml per mouse 
intraperitoneal nd then, during the time-course xperiments, 
further doses of 0.1 ml administered at approx. 90 min in- 
tervals. 
2.4. NMR spectroscopy 
The experiments were performed at 73.836 MHz using a 
vertical-bore Oxford Instruments magnet and a Bruker spec- 
trometer. A 0.7 cm diameter double-turn surface coil tuned to 
3lp and 1H was positioned above the tumour. Magnetic field 
homogeneity was adjusted whilst observing the proton signal. 
Spectra were collected as 2048 data points and were the result 
of  256 transients. The sweep width was 3000 Hz, the recycle 
time was 3.5 s and the pulse width used corresponded to a max- 
imum signal intensity. 
Spectra were transformed using a combination of trapezoidal 
and exponential multiplication, with a trapezoidal constant of 
4 and a line broadening of 20 Hz. Peak areas were obtained by 
triangulation. Intracellular pH values were calculated from the 
chemical shift difference between PCr and Pi using the equation 
pH = 6.75 + log(S - 3.27)/5.69 - S). 
3. RESULTS 
3.1. Radiobiological hypoxic fraction (RHF) 
Hypoxic fractions in tumours are usually deter- 
mined by in vitro assay of ceils irradiated in vivo. 
Comparison of cellular survival in tumours where 
the blood supply is temporarily occluded uring ir- 
radiation by clamping, with data from unclamped 
tumours allows the estimation of RHF [16]. 
Following treatment of unanaesthetized mice with 
hydralazine (5mg/kg, i.v.) the RHF in RIF-I and 
KHT tumours increased to 100o70 (fig. 1) from their 
normal evels of approx. 1 and 10%, respectively. 
The surviving cell fractions (SCF) of KHT cells 
(following 14 Gy irradiation) taken from tumours 
in which the blood supply was temporarily oc- 
cluded was 10-fold higher than that of cells from 
unclamped tumours. The mean SCF (SCF) in- 
creased from 0.71 x 102 (0.52-0.91: standard error 
of the geometric mean) to 6.1 × 102 (5.7-6.5). The 
value corresponds to the SCF from a completely 
radiobiologically h poxic population. An increase 
in SCF to 6.1 × 102 (5.2-7.1) was also observed in 
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Fig.1. Surviving fraction of KHT and RIF-1 tumour cells at 
various times after treatment with hydralazine. The lower 
dashed line gives survival of cells for mice receiving radiation 
only (i.e. these are control hypoxic fractions of 10% in KHT 
and 1% in RIF-1). The upper dashed line gives survival of cells 
from clamped tumours, i.e. the hypoxic fraction is equal to 
100%. Curves were fitted by eye. 
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Fig.2. Tumour spectra, control and 1 h post-hydralazine. 
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tumours from mice treated with hydralazine up to 
30 min prior to irradiation. The effect of 
hydralazine was transient. The SCF returned to 
normal values at 2-3  h post-hydralazine. Hydrala- 
zine also induced 100070 radiobiological hypoxia in 
the RIF-2 tumour except hat a longer period was 
required for the SCF to approximate normal evels 
(fig.l). 
In some experiments, KHT-bearing mice were 
anaesthetized, injected with hydralazine 1 h later 
and maintained under anaesthesia for a further 3 h 
before irradiation. The SCF following this treat- 
ment was 6.9 x 10 2 (4.6-8.5), a value similar to 
that for the clamped response. This contrasts with 
the results obtained with hydralazine at 3 h when 
anaesthetic was not used, i.e. the SCF returned to 
control values. Anaesthetic alone for 3 h caused a 
small increase in SCF to 1.8 x 102 (1.2-2.5). 
3.2. NMR 
In one series of experiments, the animals were 
anaesthetised, placed in the magnet for a control 
spectrum, removed for hydralazine injection, and 
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then returned to the magnet to follow the time 
course of the response. Fig.2 shows representative 
31p-NMR spectra from untreated tumours (A) and 
from tumours in mice treated 1 h previously with 
hydralazine (B). In each tumour examined the 
spectra showed a decline in high-energy 
metabolites (PCr and ATP) and an increase in the 
inorganic (Pi) peak. In many cases, the post- 
hydralazine spectra consisted solely of the Pi peak. 
Even after 4 h, there was no observed recovery in 
the spectra from any of the RIF-1, KHT or 16/C 
tumours when the mice were maintained under 
anaesthesia (see fig.3A for RIF-1 and KHT). 
In a second series of experiments (on RIF-1 and 
KHT tumours) the effect of anaesthetic was 
minimized by giving a single dose of anaesthesia 
just before collection of the NMR spectra. This 
was not done on the 16/C tumour as there was no 
comparative RHF data. Fig.3B shows, for in- 
dividual tumours, data from various times after 
hydralazine injection. During the 1.5 h after 
hydralazine treatment, 4 RIF-1 tumours had only 
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Fig.3. Metabolite ratios from RIF-1 and KHT tumours. (A) Tumour spectra collected serially from the same animal. Each line 
represents a different animal. (B) Spectra were collected from different animals, each anaesthetized immediately prior to examination. 
The control point represents x + SD (RIF-1, n = 7; KHT, n = 9). 
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ratios were approached before 3 h post-treatment, 
showing that the tumours were recovering over a 
time scale similar to that for recovery of RHF in 
unanaesthetised mice. The KHT data, although 
more scattered, also appears to show an increase in 
Pi (relative to ATP), followed by some degree of 
recovery. The more rapid recovery is consistent 
with the more rapid recovery of a control RHF in 
KHT tumours. 
The control pH values were 7.06 +_ 0.15 (KHT, 
n = 5), 7.09 +_ 0.18 (RIF-1, n = 7), and 7.20 +_ 0.20 
(16/C, n = 4). In the experiments where individual 
animals were examined, the pH decreased in KHT 
tumours from the control value to 6.77 +_ 0.12 (p < 
0.05) in animals measured up to 2.8 h post- 
hydralazine. The mean pH returned to 7.07 _+ 0.11 
in the post 3 h group. Changes in pH were not 
measured in the RIF-1 tumour because of the 
absence of a reference PCr peak immediately 
following hydralazine treatment. 
hypoxic and then showed signs of recovery. In con- 
trast, when hydralazine was administered after 
anaesthetic and the time course followed with the 
mouse maintained under anaesthesia, there was no 
sign of recovery in either tumour after 4 h. 
The three tumours used in this study, although 
of different origin and histological type, are all 
highly anaplastic transplantable tumours with high 
growth fraction. Transplantable murine tumours 
may not be ideal models therefore, for in- 
vestigating any relationships between the degree of 
tumour hypoxia and energy status in primary 
human tumours where the degree of differentia- 
tion, growth rate, and other kinetic parameters 
may be different. It is encouraging however that 
hydralazine appears to substantially increase 
hypoxia as measured by RHF in the 2 tumours 
where RHF can be measured directly and, as 
measured by 31P-NMR, in all 3 tumours used in 
this study. 
4. DISCUSSION 
The fraction of cells that are radiobiologically 
hypoxic can be measured by assaying tumour cell 
survival in vitro following irradiation in vivo. 
Following treatment with hydralazine, both the 
RIF-1 and KHT tumours became 100°70 hypoxic. 
The administration of hydralazine also had a 
marked effect upon the metabolism in the three 
tumour types, as measured by 31p-NMR. In ex- 
periments where the same animal was used for con- 
trol and post-hydralazine spectra the proportion of 
Pi relative to ATP and PCr increased and, in KHT, 
the pH decreased. This is consistent with changes 
expected on the basis of increased tumour hypoxia. 
It also indicates that anaerobic glycolysis is unable 
to provide sufficient ATP for tumour metabolism 
under these ischemic conditions. From these data 
one may conclude that, under these conditions, 
31p-NMR data can be used to predict changes in 
RHF. The similar time courses observed when us- 
ing both NMR and RHF suggest hat there is a 
relationship between hydralazine treatment, ox- 
ygen delivery and energy status. 
The effect of hydralazine on both the NMR 
spectra and RHF is dependent upon the duration 
of anaesthesia. Both studies indicated that during 
the time course of hydralazine treatment in a non- 
anaesthetized state, the tumours first became more 
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